CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03118180|
Recruitment Status : Unknown
Verified April 2017 by He Huang, Zhejiang University.
Recruitment status was: Recruiting
First Posted : April 18, 2017
Last Update Posted : April 18, 2017
Innovative Cellular Therapeutics Co., Ltd.
Information provided by (Responsible Party):
He Huang, Zhejiang University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||December 31, 2020|